
## Carolina Sales Vieira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8585819/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Factors associated with missing strings and expulsion after postplacental insertion of copper T380A intrauterine devices. International Journal of Gynecology and Obstetrics, 2022, 157, 67-75.	1.0	4
2	Drospirenone: a Latin American perspective for oestrogen-free oral contraception. European Journal of Contraception and Reproductive Health Care, 2021, 26, 73-78.	0.6	1
3	Practical training of health care providers in insertion of contraceptive implants: findings from two Brazilian centres. European Journal of Contraception and Reproductive Health Care, 2021, 26, 499-502.	0.6	3
4	Pharmacodynamics and pharmacokinetics of a copper intrauterine contraceptive system releasing ulipristal acetate: A randomized proof-of-concept study. Contraception, 2021, 104, 327-336.	0.8	1
5	Intracervical block for levonorgestrel-releasing intrauterine system placement among nulligravid women: a randomized double-blind controlled trial. American Journal of Obstetrics and Gynecology, 2020, 222, 245.e1-245.e10.	0.7	7
6	Effect of the levonorgestrelâ€releasing intrauterine system on cardiovascular risk markers among women with thrombophilia or previous venous thromboembolism. International Journal of Gynecology and Obstetrics, 2020, 148, 381-385.	1.0	4
7	Predictors of severe pain during insertion of the levonorgestrel 52â€ <sup>-</sup> mg intrauterine system among nulligravid women. Contraception, 2020, 102, 267-269.	0.8	1
8	Sociodemographic factors and prenatal care behaviors associated with unplanned pregnancy in a Brazilian birth cohort study. International Journal of Gynecology and Obstetrics, 2020, 151, 237-243.	1.0	2
9	Best Practices for Counseling Adolescents about the Etonogestrel Implant. Journal of Pediatric and Adolescent Gynecology, 2020, 33, 448-454.	0.3	19
10	Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use?. Contraception, 2019, 100, 264-268.	0.8	15
11	Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials. Contraception, 2019, 100, 438-444.	0.8	10
12	A pilot study of levonorgestrel concentrations and bleeding patterns in women with epilepsy using a levonorgestrel IUD and treated with antiepileptic drugs. Contraception, 2019, 99, 251-255.	0.8	4
13	Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial. Contraception, 2019, 100, 258-263.	0.8	9
14	Factors associated with nonadherence to instructions for using the Nestorone®/ethinyl estradiol contraceptive vaginal ring. Contraception, 2018, 97, 415-421.	0.8	15
15	Contemporary Hormonal Contraception and the Risk of Breast Cancer. New England Journal of Medicine, 2018, 378, 1263-1266.	13.9	18
16	The telomere attrition rate is not accelerated in women born small for gestational age: A birth cohort study. Gene, 2017, 600, 16-20.	1.0	5
17	Timing of Etonogestrel-Releasing Implants and Growth of Breastfed Infants. Obstetrics and Gynecology, 2017, 130, 100-107.	1.2	17
18	Cytomegalovirus Urinary Shedding in HIV-infected Pregnant Women and Congenital Cytomegalovirus Infection. Clinical Infectious Diseases, 2017, 65, 405-413.	2.9	21

#	Article	IF	CITATIONS
19	Does the Access to Sun Exposure Ensure Adequate Levels of 25-Hydroxyvitamin D?. Revista Brasileira De Ginecologia E Obstetricia, 2017, 39, 102-109.	0.3	4
20	Nutritional Counseling Promotes Changes in the Dietary Habits of Overweight and Obese Adolescents with Polycystic Ovary Syndrome. Revista Brasileira De Ginecologia E Obstetricia, 2017, 39, 692-696.	0.3	9
21	Safety of hormonal contraception for obese women. Expert Opinion on Drug Safety, 2017, 16, 1387-1393.	1.0	12
22	Cardiovascular risk markers among obese women using the levonorgestrel-releasing intrauterine system: A randomised controlled trial. Obesity Research and Clinical Practice, 2017, 11, 687-693.	0.8	9
23	Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits. Open Access Journal of Contraception, 2017, Volume 8, 13-23.	0.6	32
24	PRENACEL – a mHealth messaging system to complement antenatal care: a cluster randomized trial. Reproductive Health, 2017, 14, 146.	1.2	32
25	Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy. European Journal of Contraception and Reproductive Health Care, 2016, 21, 285-289.	0.6	3
26	Long-Acting Reversible Contraceptives: An Important Approach to Reduce Unintended Pregnancies. Revista Brasileira De Ginecologia E Obstetricia, 2016, 38, 207-209.	0.3	4
27	Neurologist knowledge about interactions between antiepileptic drugs and contraceptive methods. International Journal of Gynecology and Obstetrics, 2016, 134, 264-267.	1.0	17
28	Emergency Contraception for Adolescents and Young Adults: Guidance for Health Care Professionals. Journal of Adolescent Health, 2016, 58, 245-248.	1.2	20
29	Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects. Reproductive Sciences, 2016, 23, 877-884.	1.1	10
30	Add-back therapy with GnRH analogues for uterine fibroids. The Cochrane Library, 2015, 2015, CD010854.	1.5	28
31	Effects of two contraceptives containing drospirenone on blood pressure in normotensive women. Blood Pressure Monitoring, 2015, 20, 310-315.	0.4	9
32	Combined Oral Contraceptive for Treatment of Women with Uterine Fibroids and Abnormal Uterine Bleeding: A Systematic Review. Gynecologic and Obstetric Investigation, 2015, 79, 145-152.	0.7	17
33	Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction, 2015, 150, R11-R24.	1.1	69
34	Presentation and treatment of uterine leiomyoma in adolescence: a systematic review. BMC Women's Health, 2015, 15, 4.	0.8	49
35	Sexual Function of Women Practicing Sex in Nonconventional Settings. Journal of Sex and Marital Therapy, 2015, 41, 294-303.	1.0	1
36	Low-dose progestin-releasing contraceptives are associated withÂaÂhigher pain threshold in healthy women. Fertility and Sterility, 2015, 104, 1182-1189.	0.5	9

CAROLINA SALES VIEIRA

#	Article	IF	CITATIONS
37	Immediate postpartum initiation of etonogestrel-releasing implant: A randomized controlled trial on breastfeeding impact. Contraception, 2015, 92, 536-542.	0.8	36
38	Body Composition Characteristics Predict Sexual Functioning in Obese Women With or Without PCOS. Journal of Sex and Marital Therapy, 2015, 41, 227-237.	1.0	24
39	Effect of intracervical anesthesia on pain associated with the insertion of the levonorgestrel-releasing intrauterine system in women without previous vaginal delivery: a RCT. Human Reproduction, 2014, 29, 2439-2445.	0.4	15
40	Comparison of the hemostatic effects of a levonorgestrel-releasing intrauterine system and leuprolide acetate in women with endometriosis: A randomized clinical trial. Thrombosis Research, 2014, 134, 1193-1197.	0.8	4
41	Effect of Antiretroviral Therapy Including Lopinavir/Ritonavir or Efavirenz on Etonogestrel-Releasing Implant Pharmacokinetics in HIV-Positive Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 378-385.	0.9	59
42	Small for gestational age babies are not related to changes in markers of adipose tissue dysfunction during reproductive age. Early Human Development, 2014, 90, 231-235.	0.8	9
43	New Developments in Vaginal Rings for Contraception. Current Obstetrics and Gynecology Reports, 2014, 3, 143-149.	0.3	2
44	Oral anticoagulant therapy does not modify the bleeding pattern associated with the levonorgestrel-releasing intrauterine system in women with thrombophilia and/or a history of thrombosis. Contraception, 2014, 89, 48-53.	0.8	8
45	Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium. Contraception, 2013, 87, 766-772.	0.8	15
46	Three-dimensional ultrasound imaging of an intrauterine device showing copper corrosion. Ultrasound in Obstetrics and Gynecology, 2013, 42, 606-607.	0.9	2
47	The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception, 2012, 86, 268-275.	0.8	24
48	Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial. Thrombosis Research, 2012, 130, 355-360.	0.8	17
49	Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound in Obstetrics and Gynecology, 2012, 39, 341-347.	0.9	47
50	Oral Contraceptive Containing Chlormadinone Acetate and Ethinylestradiol Reduces Plasma Concentrations of Matrix Metalloproteinaseâ€2 in Women with Polycystic Ovary Syndrome. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 211-216.	1.2	4
51	Endocrine Disrupters: Potential Risk Factors Affecting Sexual Function in Both Men and Women. Journal of Sexual Medicine, 2012, 9, 941-942.	0.3	8
52	Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome. Molecular and Cellular Biochemistry, 2011, 353, 251-257.	1.4	37
53	The Frequency of Metabolic Syndrome is Higher Among PCOS Brazilian Women With Menstrual Irregularity Plus Hyperandrogenism. Reproductive Sciences, 2011, 18, 1230-1236.	1.1	30
54	Contracepção hormonal e sistema cardiovascular. Arquivos Brasileiros De Cardiologia, 2011, 96, e81-e89.	0.3	33

#	Article	IF	CITATIONS
55	Absence of adverse hepatic or renal effects with the etonogestrel-releasing contraceptive implant inserted immediately postpartum. Open Access Journal of Contraception, 2010, , 127.	0.6	Ο
56	High prevalence of polycystic ovary syndrome in women born small for gestational age. Human Reproduction, 2010, 25, 2124-2131.	0.4	90
57	Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception, 2010, 81, 117-122.	0.8	41
58	Unfavorable lipid profile in women with endometriosis. Fertility and Sterility, 2010, 93, 2433-2436.	0.5	84
59	Ethinylestradiol and estradiol have different effects on oxidative stress and nitric oxide synthesis in human endothelial cell cultures. Fertility and Sterility, 2010, 94, 1578-1582.	0.5	18
60	Reply of the Authors: Calling attention to the use of false "endothelial―cell lines. Fertility and Sterility, 2010, 93, e34.	0.5	0
61	Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium. Human Reproduction, 2009, 24, 2736-2745.	0.4	46
62	Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome?. Clinical Endocrinology, 2009, 71, 406-411.	1.2	69
63	Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. International Journal of Clinical Practice, 2009, 63, 160-169.	0.8	29
64	Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women. Contraception, 2009, 79, 35-40.	0.8	47
65	Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception, 2009, 80, 519-526.	0.8	81
66	Flow-mediated dilatation in polycystic ovary syndrome women. Fertility and Sterility, 2009, 91, e23.	0.5	4
67	Tibolone in postmenopausal women with systemic lupus erythematosus: A pilot study. Maturitas, 2009, 62, 311-316.	1.0	13
68	Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Human Reproduction, 2007, 22, 2196-2201.	0.4	40
69	Controlled ovarian stimulation with exclusive FSH followed by stimulation with hCG alone, FSH alone or hMG. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 130, 99-106.	0.5	16
70	The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertility and Sterility, 2007, 87, 1231-1234.	0.5	33
71	Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome. Fertility and Sterility, 2007, 88, 519-522.	0.5	14
72	Title is missing!. Fertility and Sterility, 2007, 88, 765-766.	0.5	0

#	Article	IF	CITATIONS
73	The levonorgestrel-releasing intrauterine system (LNG-IUS) and endometriosis: molecular effects onÂthe topic and on the ectopic endometrium. Fertility and Sterility, 2007, 88, S209-S210.	0.5	0
74	Hormônios femininos e hemostasia. Revista Brasileira De Ginecologia E Obstetricia, 2007, 29, 538-547.	0.3	5
75	Avaliação da função das células beta pancreáticas através do modelo matemático de HOMA em portadoras de sÃndrome dos ovários policÃsticos: comparação entre obesas e não-obesas. Revista Brasileira De Ginecologia E Obstetricia, 2007, 29, 141-146.	0.3	1
76	Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women. Thrombosis and Haemostasis, 2005, 94, 682-683.	1.8	9
77	LH as a low dose chorionic gonadotropin for late stage ovulation induction: comparison with human menopausal gonadotropin. International Congress Series, 2004, 1271, 89-92.	0.2	0
78	Progesterone receptor, bc1-2 and bax expression in meningiomas. Journal of Neuro-Oncology, 2002, 56, 35-41.	1.4	15